Savara, Inc. (SVRA)

[fl89808]

On November 28, 2017, Savara Inc. (“Savara”) entered into Amendment No. 1, effective September 30, 2017, to the Research Program Award Letter Agreement between Savara and Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”) dated September 30, 2013 (as amended, the “Award Agreement”), pursuant to which the amount of the development award available to Savara was increased by $5,000,000 to an aggregate of $6,700,000. CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, and the award is available to support the continued development of Savara’s AeroVanc program. The award can be drawn down by Savara as needed upon the achievement of certain milestones set forth in the Award Agreement.